Pertaining to dissociative brokers (typically ketamine) or a combination of ketamine and an ?2 adrenergic receptor agonist, like xylazine, there is limited dialogue of the euthanasia process in The present AVMA recommendations,5 with only one supporting review cited during which the key goal wasn't qualitative evaluation of dissociative agents for